BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9068226)

  • 1. From serendipity to design: the evolution of drug development in oncology.
    Markman M; Peereboom DM
    Cleve Clin J Med; 1997 Mar; 64(3):155-63. PubMed ID: 9068226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 3. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discovery and development in the pharmaceutical industry.
    Schacter LP; Anderson C; Canetta RM; Kelley S; Nicaise C; Onetto N; Rozencweig M; Smaldone L; Winograd B
    Semin Oncol; 1992 Dec; 19(6):613-21. PubMed ID: 1462163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated approval of oncology products: a decade of experience.
    Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
    J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current impact of natural products in the discovery of anticancer drugs].
    Monneret C
    Ann Pharm Fr; 2010 Jul; 68(4):218-32. PubMed ID: 20637355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory considerations for preclinical development of anticancer drugs.
    DeGeorge JJ; Ahn CH; Andrews PA; Brower ME; Giorgio DW; Goheer MA; Lee-Ham DY; McGuinn WD; Schmidt W; Sun CJ; Tripathi SC
    Cancer Chemother Pharmacol; 1998; 41(3):173-85. PubMed ID: 9443633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [From molecule to medicine--drug development].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355
    [No Abstract]   [Full Text] [Related]  

  • 10. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.
    Sausville EA; Feigal E
    Ann Oncol; 1999 Nov; 10(11):1287-91. PubMed ID: 10631454
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA starts moving on critical path, but initiative running out of steam.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
    [No Abstract]   [Full Text] [Related]  

  • 13. Pediatric drug research--the road less traveled.
    Holdsworth MT
    Ann Pharmacother; 2003 Apr; 37(4):586-91. PubMed ID: 12659620
    [No Abstract]   [Full Text] [Related]  

  • 14. NCI, FDA to collaborate on speeding up drug discovery.
    Arnold K
    J Natl Cancer Inst; 2003 Aug; 95(16):1192. PubMed ID: 12928341
    [No Abstract]   [Full Text] [Related]  

  • 15. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 16. Imaging as a tumor biomarker in oncology drug trials for lung cancer: the FDA perspective.
    Petrick N; Brown DG; Suleiman O; Myers KJ
    Clin Pharmacol Ther; 2008 Oct; 84(4):523-5. PubMed ID: 18716616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncology drug review process.
    Farrell AT; Pazdur R
    J Natl Compr Canc Netw; 2003 Jan; 1(1):109-13. PubMed ID: 19764154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Business barriers slowing the pace of cancer immunotherapy research and development.
    Tuma RS
    J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
    [No Abstract]   [Full Text] [Related]  

  • 20. Ophthalmic drug development: procedural considerations.
    Novack GD
    J Glaucoma; 1998 Jun; 7(3):202-9. PubMed ID: 9627860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.